Treatment strategies for COVID-19 in organ transplant recipients under the new normal
10.3760/cma.j.cn421203-20230615-00005
- VernacularTitle:新常态下器官移植受者新型冠状病毒感染诊疗策略
- Author:
Chunrong JU
1
;
Xin XU
;
Jianxing HE
;
Nanshan ZHONG
Author Information
1. 广州医科大学附属第一医院呼吸健康研究院，国家呼吸医学中心，国家呼吸疾病临床研究中心，呼吸疾病国家重点实验室，广州 510120
- Keywords:
Organ transplantation;
Solid organ transplantation;
SARS-CoV-2;
Antiviral therapy;
Small molecule pharmaceutical;
Diagnosis
- From:
Chinese Journal of Organ Transplantation
2023;44(10):603-611
- CountryChina
- Language:Chinese
-
Abstract:
Currently COVID-19 variant virology and its prevalence both domestically and internationally have become a new norm.With the emergence of Omicron variant, the protective effect of original preventive measures against reinfection with variant strains has declined.Current prevalence of COVID-19 variant strains, the mechanisms of reinfection and the risks of reinfection in solid organ transplant recipients(SOTR)were discussed.Immunocompromised individuals, especially SOTR, face an elevated risk of multiple infections, such as seasonal influenza and respiratory syncytial virus, during high transmission seasons for respiratory viruses and require special care and protection.With the introduction of several small molecule drugs, there are now more options available for antiviral regimens.This review offered a brief overview of the characteristics of COVID-19 variant strains in the current scenario, disease incidence among SOTR in China, unique features of novel antiviral agents and optimizing the selection of diagnostic and therapeutic plans.
